Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
USA TODAY on MSN10d
Here's why researchers think most people stop taking weight loss drugs within a yearNearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) said Wednesday its drug Victoza has been shown in a clinical study to be more efficient than a competing drug in improving diabetes ...
Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...
Novo Nordisk sells the drug semaglutide under the brands Ozempic for diabetes and Wegovy for weight loss. The company's older weight loss drug, liraglutide, is marketed as Victoza for diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback